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Abstract
Enterohemorrhagic and enteropathogenic E. coli (EHEC and EPEC) can cause severe and potentially life-threatening
infections. Their pathogenicity is mediated by at least 40 effector proteins which they inject into their host cells by a type-III
secretion system leading to the subversion of several cellular pathways. However, the molecular function of several effectors
remains unknown, even though they contribute to virulence. Here we show that one of them, NleF, binds to caspase-4, -8,
and -9 in yeast two-hybrid, LUMIER, and direct interaction assays. NleF inhibits the catalytic activity of the caspases in vitro
and in cell lysate and prevents apoptosis in HeLa and Caco-2 cells. We have solved the crystal structure of the caspase-9/
NleF complex which shows that NleF uses a novel mode of caspase inhibition, involving the insertion of the carboxyterminus of NleF into the active site of the protease. In conformance with our structural model, mutagenized NleF with
truncated or elongated carboxy-termini revealed a complete loss in caspase binding and apoptosis inhibition. Evasion of
apoptosis helps pathogenic E. coli and other pathogens to take over the host cell by counteracting the cell’s ability to selfdestruct upon infection. Recently, two other effector proteins, namely NleD and NleH, were shown to interfere with
apoptosis. Even though NleF is not the only effector protein capable of apoptosis inhibition, direct inhibition of caspases by
bacterial effectors has not been reported to date. Also unique so far is its mode of inhibition that resembles the one
obtained for synthetic peptide-type inhibitors and as such deviates substantially from previously reported caspase-9
inhibitors such as the BIR3 domain of XIAP.
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Eukaryotic cells recognise invading pathogens by pattern
recognition receptors, which stimulate the secretion of inflammatory mediators such as IL-1b, IL-6, TNFa and interferons to
combat the infection. In some cases, the response concludes in the
induction of apoptotic cell death to remove the invading pathogen
along with its host cell [5]. Central to the execution of apoptosis
are the caspases, a family of intracellular aspartate proteases [6]
that become activated upon initiation of apoptosis. To counteract
this response, many viruses express proteins which inhibit the
induction of apoptosis [7]. Some anti-apoptotic viral proteins act
as decoys for cellular pro-apoptotic factors, such as viral inhibitors
of apoptosis (vIAPs) [8], whereas others, such as the baculoviral
p35 protein, directly bind to caspases to inhibit their proteolytic
activity [9,10]. An example of a bacterial effector protein
counteracting an apoptotic response has recently been reported:
The EHEC and EPEC effector NleH inhibits apoptosis of host

Introduction
Pathogenic bacteria that cause infectious diarrhoea are a major
health problem worldwide. Among them, EHEC and EPEC are
especially virulent [1,2]. Like many other pathogenic gram
negative bacteria, they possess a type III secretion system
(T3SS), a syringe-like apparatus composed of more than 20
proteins, which permits injection of bacterial effector proteins
directly into mammalian host cells. EHEC strain O157:H7 (Sakai)
encodes for 62 putative effectors, of which 39 are verifiably
translocated into the host cell [3]. These proteins, many of which
are shared by EPEC, are responsible for the subversion of cellular
antagonistic responses and the establishment of an environment
suitable for pathogen proliferation. The precise function of many
of these effectors is unknown, even though some, including NleF,
have been implicated in virulence [4].
PLOS ONE | www.plosone.org
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cells by targeting BI-1 (Bax inhibitor 1), a cellular inhibitor of the
anti-apoptotic protein Bax [11]. However, direct inhibition of
caspases by bacterial effectors has not been reported to date.

NleF underwent apoptosis, as compared to 49.9% expressing
Protein A (Fig. 3D), indicating that NleF is competent to inhibit
caspase-9-dependent apoptosis in HeLa cells.

Results

Structural Basis of Caspase Inhibition by NleF
To determine how NleF inhibits caspase-9, we co-crystallized
the protein complex and determined its structure at a resolution of
3.49 Å (Table S2). Bound to NleF, caspase-9 shows the typical
fold of a mostly parallel six-stranded b-sheet sandwiched between
two layers of a-helices and forms a dimer arranged in a similar
geometry to that described for unbound caspase-9 [12]. NleF folds
into a four-helix bundle connected by a two-stranded b-sheet
between a-helices 2 and 3 as well as extended loop regions
between the a-helices. A Dali search [13] for closest structural
neighbours of NleF produces results with a Z-score of 6.4 or lower,
indicative of only limited topological similarity to PDB-deposited
protein structures. Each caspase monomer bears one NleF
molecule bound via multiple interactions of the substrate
recognition site of the caspase to the effector protein (Fig. 4A,
Fig. S4). The interaction interface between caspase-9 and NleF
comprises 902 and 1017Å2 of the two proteins, respectively.
Despite moderate crystallographic resolution, the omit Fo-Fc
difference electron density map allows for an unambiguous
interpretation of the NleF interaction mode (Fig. 4B). In contrast
to the published structure of a caspase-9 dimer, with one active
and one inactivated protease monomer [12] per asymmetric unit,
in the NleF-bound state, both caspase molecules are trapped in a
binding-competent (but proteolytically inactive) state with wellestablished subpockets. The C-terminal amino acids Gly189,
Cys188, Gln187 and Leu186 of NleF anchor the effector protein
to the S1, S2, S3, and S4 pocket of the protease, respectively
(Fig. 4C). The S1 pocket that typically recognizes the P1 aspartate
residue harbours Gly189 of NleF while the C-terminal main chain
carboxylate group of this moiety partly mimics the interactions of
the Asp side chain carboxylate. The side chains of Arg179 and
Arg341 are involved in electrostatic interactions/salt bridges to
NleF Gly189, whereas Cys188 occupies the S2 pocket of the
protease, which mainly consists of the space between the aromatic
side chains of Trp340 and His237. This pocket typically tolerates
only amino acid side chains of small and aliphatic nature such as
Ala and Val [14]. NleF Gln187 occupies the protease S3 pocket
and mainly interacts with the Arg341 peptide NH group via its
main chain carbonyl oxygen and forms a charge-assisted H-bond
from the Gln side chain carbonyl to the positively charged Arg177
side chain. The S4 pocket is occupied by NleF Leu186 which
establishes van der Waals contacts to the aromatic side chains of
Trp340 and Trp348 of caspase-9.
The inhibition mode of NleF to some extent resembles the one
obtained for synthetic peptide-type inhibitors such as Z-EVDDcbmk12, where the modified Asp, Val and Glu occupy the
caspase-9 S1, S2, and S3 pockets while the benzyloxy-carbonyl
moiety is partly solvent-exposed and occupies the S4 pocket.However, the latter inhibitor seems to establish a more efficient salt
bridge between its Asp to Arg179 and Arg341, which becomes
only partly mimicked by the NleF-Gly189 C-terminus (Fig. 4D).
This inhibition mode observed for NleF deviates substantially from
previously reported caspase-9 inhibitors such as the BIR3 domain
of XIAP [15], which occupies the dimerisation interface of two
caspase-9 molecules thereby inducing a catalytically non-productive conformation of the protease (Fig. 4E). We have not been
able to detect dimerisation of NleF by itself (Fig. S5). Interestingly,
despite the overall structure of the caspase dimer and the type of
dimerisation, caspase-9 structures share high similarities for the
NleF-bound caspase presented in this contribution and the dimer

NleF Binds to Caspases
In a systematic effort to elucidate the cellular targets of EHEC
effector proteins, we identified caspase-9 as a binding partner of
NleF. Caspase-9 was the predominant hit identified in screens of
NleF against amino- and carboxy-terminally tagged yeast twohybrid libraries (see Methods for details). LUMIER assays with
caspase-9 and NleF in HEK-293T cells confirmed the interaction.
A test for interaction of NleF with caspases-1, -2, -3, -4, -6, -7, -8, 9, -10 and -14 led to the identification of caspase-4 and caspase-8
as additional binding partners (Fig. 1A). We determined the
dissociation constant of the Caspase9-NleF interaction by surface
acoustic wave resonance (SAW) to be ,39 nM, a value which is
well in the range of known viral inhibitors of apoptosis [7],
indicating biological significance (Fig. 1B, C, Table S1).

NleF Inhibits Human Caspases-4, -8, and -9
Binding of NleF to purified caspase-4, -8, and -9 resulted in
potent inhibition of all three caspases (Fig. 2A, Fig. S1). The
inhibitory activity of NleF was lost after proteinase K treatment,
excluding a contribution from non-proteinaceous contaminants.
To accesss the inhibition of caspase activity in vitro by NleF in a
dose-dependent way serial dilutions of NleF were tested for their
effects on caspase activity and the IC-50 of NleF for inhibition of
caspase-4, -8 and -9 were determined to be 14 nM, 40 nM and
83 nM (Fig. 2B–D). NleF, but not proteolytically inactivated
NleF, significantly inhibited caspase activity in extracts of HeLa
cells induced to enter apoptosis with TRAIL (Tumor Necrosis
Factor Related Apoptosis Inducing Ligand; Fig. 2E). A reduction
in caspase-9 activity was also observed in lysates of TRAIL-treated
HeLa cells expressing the apoptosis-inhibitory protein BCL2 or
wild type NleF, respectively, whereas expression of an interactiondeficient mutant of NleF (NleF 1–160, see Fig. S2) had no effect
on caspase-9 activity (Fig. 2F).

NleF Prevents the Induction of Apoptosis
To test if caspase inhibition by NleF can prevent the induction
of apoptosis, we transiently expressed NleF as well as known
inhibitors of apoptosis in HeLa cells prior to induction of apoptosis
with TRAIL. The fraction of cells entering TRAIL-induced
apoptosis as assessed by annexin V staining was markedly reduced
in HeLa cells expressing YFP-tagged NleF (6.5%) compared to
cells expressing a Protein A control construct (42.8%). The
magnitude of this effect was comparable to the effect of known
inhibitors of apoptosis, such as XIAP (6.1%) and BCL2 (13.4%,
Fig. 3A, C and Fig. S3). Experiments in Caco-2 colon
carcinoma cells confirmed these observations (7.0% versus
25.2% induction for NleF- and Protein A- expressing cells,
respectively; Fig. 3B). Cells expressing Protein A or an inactive
fragment of NleF (amino acids 1–160) showed no significant
reduction in apoptosis (Fig. 3B).
TRAIL triggers apoptosis through the extrinsic pathway, which
is executed via caspase-8 as the initiator caspase (Fig. S1).
However, caspase-9 has been shown to be essential for execution
of TRAIL-induced apoptosis of many somatic cells, including
HeLa and Caco-2. To test if the anti-apoptotic effect of NleF is of
comparable strength when caspase-9 is the only initiator caspase
involved, we repeated the experiments using staurosporine as an
inducer of intrinsic apoptosis. Only 3.7% of HeLa cells expressing
PLOS ONE | www.plosone.org
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Figure 1. NleF binds caspases -4, -8 and -9. A. Binding of NleF to caspases-4, -8 and -9 using luciferase-NleF and protein-A-caspase fusions
(LUMIER assays34). Interaction strengths are expressed as signal to background ratios using binding to protein A as a negative control. The interaction
of JUN to FOS serves as a positive control. Squares indicate individual measurements. B,C. The affinity constant (Kd) of NleF binding to immobilized
caspase-9 as measured by surface acoustic wave (SAW) technology is ,39 nM. The Kd is defined as follows: Kd = Koff/Kon = y-intercept/slope (C), SAW
overlay plot of NleF injections. NleF concentrations are indicated in the legend. The two bold curves added to each NleF measurement (on the left
and right of the peak) represent the optimal Kobs and Koff curves.
doi:10.1371/journal.pone.0058937.g001

inhibited by Z-EVD-Dcbmk12 (Fig. 4F). However, in the present
complex both caspase monomers are captured in a productive
state with well established specificity pockets. Thus, with respect to
the caspases, the two crystal structures mainly differ in the
conformation of the loop beginning with Ala284 bearing the active
site Cys285, which becomes undefined after Gly287 in the
previously reported structure and is defined to Ser298 in the
NleF-bound complex. In addition, consistent with this active
conformation the loop region Ser332–Ser347 between strand 7
and helix E deviates between the two structures and contributes in
active state to the dimer interface (Fig. 4F).

infected with enteropathogenic E. coli (EPEC), which shares the
T3SS and many of the effectors, including an identical NleF, with
EHEC. To ensure that the effect of NleF on caspases-4, -8 and -9
were captured in the infection model, activation of the
downstream caspase-3/7 was assessed to measure apoptosis. We
detected no significant difference between wild type EPEC and an
nleF mutant in the ability to induce caspase 3/7 activation (Fig. 5),
indicating that under these conditions and in the context of the full
repertoire of effector proteins NleF does not play a dominant role.
However, we did find a significant difference in apoptosis between
the cell lines infected with the nleF mutant complemented in single
copy with the wild type nleF allele and the mutant similarly
complemented with a caspase interaction-deficient nleF allele (NleF
with the last four amino acids deleted, see also below). The ability
to detect this difference in the complemented strains can be

Effect of NleF in an Infection Model
To determine whether NleF can inhibit apoptosis when injected
into cells via the type III secretion apparatus, HeLa cells were

PLOS ONE | www.plosone.org
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Figure 2. NleF inhibits caspases in vitro and in in cells. A. In vitro inhibition of caspase-4 (1 U), caspase-8 (1 U) and caspase-9 (1 U) by NleF
(1.5 mg) (1.5 mg/unit caspase), the inhibitor Z-VAD-fluoromethylketone (Z-VAD-FMK, 20 mM), and proteinase K-inactivated NleF (1.5 mg). B-D. Dosedependent inhibition of purified caspase-4, -8, and -9 by NleF (logarithmic concentration indicated in the X axis): B. Caspase-4 (200 nM). C. caspase-8

PLOS ONE | www.plosone.org
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(68 nM). D. caspase-9 (1.1 mM). E. Recombinant NleF inhibits caspase-9 activity in lysates of apoptotic cells. HeLa cells were induced to enter
apoptosis by treatment with TRAIL (25 ng/ml) for four hours (black bars) or left untreated (striped bars) before preparation of lysates and
measurement of cellular caspase-9 activity in the absence or presence of an abundant amount of purified NleF. F. Caspase-9 activity in apoptotic
HeLa cell extracts expressing Protein A, an inactive fragment of NleF (amino acids 1–160), wild type NleF or BCL2, respectively. Significance was
determined using the two-tailed unpaired Student’s t-test. *p,0.05; **p,0.01; ***p,0.001; ****p,0.0001.
doi:10.1371/journal.pone.0058937.g002

Figure 3. NleF inhibits apoptosis induced by TRAIL and staurosporine. A–C. Percentage of apoptotic HeLa and Caco-2 cells in TRAIL (25 ng/
ml) treated (+) and untreated (2) samples. A. HeLa cells expressing YFP-fusions of wild type NleF, XIAP and BCL2, respectively, exhibited decreased
apoptosis in comparison to cells expressing Protein A or an inactive NleF fragment (amino acids 1–160) after TRAIL treatment. Squares: percentage of
apoptotic cells (three independent experiments); bars: average. B. Caco-2 cells expressing NleF and Protein A, respectively. Significance (t-test):
*P,0.05. C. Representative FACS counts of HeLa cells expressing the indicated YFP-tagged constructs. Cells that stained positive for annexin Vallophycocyanine (APC+) but negative for propidium iodide were counted as apoptotic cells. D. Percentage of apoptotic HeLa cells in staurosporine
treated (+) and untreated (2) samples expressing NleF and Protein A, respectively.
doi:10.1371/journal.pone.0058937.g003
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Figure 4. Crystal structure of Caspase-9 with bound NleF. A. The caspase-9 protease monomers are shown in magenta and yellow, the active
site cysteines (Cys285) are shown as red sticks for improved special orientation of the catalytic site. The NleF effector proteins attached to the caspase
active sites are shown in green, as labeled in the figure. B. The C-terminal residues of NleF are anchoring the effector protein to the specificity pockets
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of the protease. The Fo-Fc omit electron density contoured at 2.5 s is shown in blue for a representative part of the involved C-terminal NleF
residues. C. Detailed binding mode of the NleF C-terminus to the caspase-9 active site. Involved amino acids are shown as green and yellow sticks,
hydrogen bonds are depicted as magenta dashed lines. D. Superposition of the NleF(green)-bound caspase-9 (yellow) with the peptide inhibitor ZEVD-Dcbmk (magenta) bound to the caspase-9 monomer (blue) captured in active state (PDB entry 1JXQ). While the conformation of caspase
residues is virtually identical, slight differences in the mode of interaction of the bound inhibitors are e.g. observed for the Asp/Gly-P1 moiety, where
the Asp of Z-EVD-Dcbmk adopts a more favourable geometry for efficient salt bridge formation to Arg179. E. Superimposition of the NleF-bound
caspase-9 dimer presented in this study and the previously described caspase-9 crystal structure (light blue) in complex with the BIR3 domain of the
XIAP inhibitor shown as red cartoon (PDB entry 1NW9). While the latter interferes with the formation of a productive caspase dimer, NleF establishes
its inhibitory activity by means of a fundamentally different mechanism of active site targeting. F. Superimposition of the caspase-9 dimer obtained
for the NleF-inhibited form (yellow and magenta as in A., both NleF molecules omitted for clarity) and the dimer of 1JXQ (grey cartoon). While the
type of dimer formation and the overall protein conformation is well conserved between the two dimers, deviations arise mainly from the fact that
one of the two 1JXQ monomers (left) corresponds to a non-productive, inactive conformation while in the NleF-inhibited dimer, both monomers
adopt an active state with well-formed specificity pockets.
doi:10.1371/journal.pone.0058937.g004

attributed to the fact that the complementation strains had higher
levels of expression than the WT strain (Fig. S6). This slightly
increased expression of NleF resulted in less caspase 3/7 cleavage
in the mutant complemented with the wild type allele in
comparison to the other strains tested (Fig. 5).

type of inhibitory interaction of the carboxy-terminus of NleF and
the active site of the caspase.

Discussion
The elimination of infected cells via apoptosis is an evolutionary
conserved defence mechanism of multicellular organisms that is
commonly used against viruses, pathogenic bacteria and other
parasites. To counteract this mechanism, many pathogens, such as
cytomegaloviruses, Mycobacterium tuberculosis and Toxoplasma gondii
have evolved mechanisms to prevent apoptosis of their host cells
[5,16,17]. The need for this countermeasure may be all the more
crucial to pathogenic E. coli as the bundle-forming pili and
effectors expressed by EPEC and/or EHEC, e.g. EspF and Map,
have been demonstrated to induce apoptosis in host cells
[18,19,20,21,22]. Despite the presence of these proapoptotic
factors, a decrease in normal apoptotic rates was observed upon
infection of rabbits with a related REPEC O103 strain [23]. EPEC
and EHEC inject into host cells a large number of effector proteins
that can influence apoptosis including pro- and anti-apoptotic
proteins. In the context of this large repertoire of effectors, loss of
NleF did not significantly change EPEC induced apoptosis, a

Validation of the Structural Model
To test the predictions of this structural model, we generated
versions of NleF with truncated or elongated C-termini, as well as
individual mutations of the carboxy-terminal four amino acids to
alanine. The effect of these alterations on binding to caspases and
inhibition of apoptosis is depicted in Fig. 6. Deletion of the last
four amino acids of the NleF carboxy-terminus or extension by a
single amino acid reduced caspase binding and anti-apoptotic
activity to background levels (Fig. 6A–D). Deletion or mutation of
single amino acids also reduced the anti-apoptotic activity, but did
not completely abolish it. In accordance with this effect,
interaction signals above background were still detectable for the
single amino acid deletion variant of NleF and caspase-9, and the
Cys188Ala mutation variant and caspase-4 and -9. These data
strongly support the conclusion drawn from the crystallographic
analysis, showing that caspase inhibition by NleF occurs by a novel

Figure 5. Caspase 3/7 activity in infected HeLa cells. HeLa cells were infected with wild type EPEC strain E2348/69, DnleF deletion mutant, or
DnleF complemented in single copy with nleF variants for 2.5 to 3 hours. Treatment of HeLa cells with staurosporine (5 mM) was used as a positive
control. There was no significant difference between caspase activity upon infection with the wild type strain and the DnleF deletion mutant,
however the deletion mutant complemented with the wild type allele consistently induced significantly less caspase 3/7 activity than the deletion
mutant complemented with the allele lacking the last 4 codons. Significance was determined using the two-tailed Wilcoxon test *p,0.02.
doi:10.1371/journal.pone.0058937.g005
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type and mutant nleF alleles resulted in slightly higher levels of
expression, even though the genes were inserted into the
chromosome in single copy. Hence, NleF indeed plays a role in
inhibiting apoptosis as expression of NleF variants unable to bind
caspase-9 resulted in increased levels of caspase 3/7 cleavage.
With caspase-9, NleF targets a bottleneck in the intrinsic
apoptotic pathway and is able to counteract apoptosis even at a
point when pro-apoptotic proteins have already been released
from mitochondria (Fig. S1). Most somatic cells, including
enterocytes (the relevant host cells for EHEC and EPEC), depend
on mitochondrially induced caspase-9 activation for induction of
apoptosis [24,25,26]. In addition to caspase-9, NleF binds to and
inhibits caspase-8, the initiator caspase triggering the extrinsic
apoptotic pathway [27]. NleF also blocks caspase-4, which has
recently been reported to be required for the activation of the
inflammasome [28]. Inhibition of caspase-4 by NleF might thus
also inhibit the inflammation response. Targeting these caspases
allows NleF to block apoptotic as well as immune response signals
before they reach the downstream executioner caspases 3/7 and
thus prevent the host cells from erasing themselves and thereby the
invading pathogen. We conclude that NleF’s interference with
these cascades contributes to the preservation of the biological
niche of EHEC, EPEC and possibly other pathogens that express
homologous effector proteins.

Materials and Methods
Oligonucleotides and Bacterial Strains
ECs1815 (nleF) was cloned from E. coli O157:H7 str. Sakai using
the GatewayH Technology (Invitrogen). Two sets of primers were
used; first the gene-specific primers (ECs1815 forw: 59- AGG CTc
cacc ATG TTA CCA ACA AGT GGT TC-39 and ECs1815 rev:
59- C TGG GTG GAT TCA TCC ACA TTG TAA AGA TCC
TTT GTT G-39), and in a second PCR step the attB primers
(attB1:59- G GGG ACA AGT TTG TAC AAA AAA GCA GGC
TCC ACC ATG-39 and attB2:59-GGG GAC CAC TTT GTA
CAA GAA AGC TGG GTG GAT TCA-39) for the attachment of
the attB sites. Cloning and PCR were performed according to the
manufacturer’s instructions. The resulting nleF PCR product was
cloned via a GatewayH BP reaction in the entry vector
pDONR221. Starting from the latter, nleF was shuttled into
pcDNA3-Rluc-GW, pTREX-dest30-ntPrA, pGBKCg, pGBT9GW and pdEYFP-C1amp [29,30,31,32].

Cell Lines, Transfection and Apoptosis Induction
Transient transfection of HeLa, Caco-2 and HEK293T cells
was done using Lipofectamine (Invitrogen). The procedure was
performed as recommended by the manufacturer. Apoptosis
induction was achieved by adding 25 ng/ml SuperKillerTrail
(ENZO Life Sciences) or 5 mM staurosporine (Roche Diagnostics)
6 h in advance of flow cytometric analysis or 4 h before lysis for
the determination of caspase-9 activity in cell lysates. Caco-2 cells
were obtained from ATCC (HTB-37). HEK293 were obtained
from DSMZ (No. ACC 305).

Figure 6. Caspase binding and apoptosis inhibition by
modified versions of NleF. A–C. Caspase-9-binding of different
versions of NleF assessed by LUMIER assays. A. Caspase-4, B. caspase-8,
C. caspase-9. D. Percentage of apoptotic HeLa cells expressing different
versions of NleF after induction with staurosporine. NleF +1: NleF with
an additional C-terminal alanine; NleF -1 and NleF -4: NleF with the
terminal 1 and 4 amino acids removed, respectively; NleF L186A, NleF
Q187A, NleF C188A and NleF G189A: NleF versions with indicated
amino acids substituted by alanine; NleF +18: NleF with additional 18
amino acids.
doi:10.1371/journal.pone.0058937.g006

Yeast Two-hybrid Pool Screening
Yeast two-hybrid (Y2H) pool screening was done as described in
Albers et al. [32]. Human libraries used in this study are the MGC
ORF collection and the universal human cDNA library (Clontech
638874). The human ORF collection is a normalized human full
length clone collection that originates from the Mammalian Gene
Collection (MGC) [33]. The whole collection was obtained as an
entry clone collection and subsequently shuttled to different
expression vectors via site specific recombination [34] using the

result consistent with the low levels of NleF expressed [4].
However, complementation of the nleF deletion mutant with wild
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GatewayH Technology (Invitrogen). The vectors used for ORF
library generation were pGAD424-GW and pGADCg, two Y2H
vectors harboring N- and C-terminal fusions to the GAL4
activation domain, respectively.

Measurement of Caspase Activity in vitro
Caspase-9 was purified as described below with specific
activities around 1000 units per mg caspase. The proteolytic
activity of purified caspase-9 was determined via Caspase-GloH 9
(Promega). This caspase was used for all experiments using
purified caspase-9 except Fig. 2 panel A, in which caspase-9 from
the Abnova caspase-9 assay kit (KA0763) had been used. Caspase4, -8 and -9 activities were measured using caspase-4, -8 and -9
inhibitor screening kits from Abnova (CASP4: KA0747, CASP8:
KA0758 and CASP9: KA0763). Purified caspases were provided
as a part of above mentioned kits. Specific activities were 1111
units for caspase-4/mg, 2500 units/mg for caspase-8, and 400
units/mg for caspase-9. For NleF inhibition, 1.5 mg NleF was
added to 1 unit of active caspase. IC-50 of caspase-4, -8, and -9
was determined using 200, 68, and 1100 nM of caspase,
respectively, using the Abnova kits for caspase-4 and -8 and the
Caspase-GloH 9 kit (Promega) for caspase-9. Concentration of
caspase active sites was determined by titration with Z-VAD-FMK
(MP Biomedicals). Fluorescence and luminescence were detected
using the Tecan InfiniteH 200 PRO series micro plate reader.
Each experiment was done at least in triplicate. IC50 values were
derived from two independent data sets done in triplicate using
GraphPad Prism Software.

Lumier Assay (LUminescence-based Mammalian
IntERactome Mapping) [35]
The method was performed as previously described [29].
Proteins were transiently expressed in HEK-293 cells as hybrid
proteins with the Staphylococcus aureus protein A tag or with the
Renilla reniformis luciferase ORF fused to their amino termini. 20 ng
of each expression construct were transfected into 10,000
HEK293 cells using 0.05 ml of lipofectamine 2000 (Invitrogen) in
96 well plates. After 40 hours, medium was removed and cells
were lysed on ice in 10 ml of ice-cold lysis buffer (20 mM Tris
pH 7.5, 250 mM NaCl, 1% TritonX-100, 10 mM EDTA,
10 mM DTT, Protease Inhibitor Cocktail (Roche), Phosphatase
Inhibitor Cocktail (Roche), Benzonase (Novagen) 0,0125 units per
ml final concentration) containing sheep-anti-rabbit IgG-coated
magnetic beads (Invitrogen, Dynabeads M280, 2 mg/ml final
concentration). Lysates were incubated on ice for 15 minutes.
100 ml of washing buffer (PBS, 1 mM DTT) were added per well,
and 10% of the diluted lysate was removed to determine the
luciferase activity present in each sample before washing. The rest
of the sample was washed 6 times in washing buffer in a Tecan
Hydroflex plate washer. Luciferase activity was measured in the
lysate as well as in washed beads. Negative controls had been
transfected with the plasmid expressing the luciferase fusion
protein and a vector expressing a dimer of protein A. For each
sample, four values were measured: the luciferase present in 10%
of the sample before washing (‘‘input’’), the luciferase activity
present on the beads after washing (‘‘bound’’), and the same values
for the negative controls (‘‘input nc’’, and ‘‘bound nc’’).
Normalised signal to background ratios are calculated as follows:
Generate ‘‘signals normalised for expression levels’’ by calculating
‘‘bound’’/‘‘input’’ for both the interaction test (X-protein A+ Yluciferase) and the negative control (protein A alone+Y luciferase
[‘‘bound nc’’/‘‘input nc’’]). Divide the ‘‘signals normalised for
expression levels’’ of the interaction test by the ‘‘signals normalised
for expression levels’’ of negative control to derive signal to
background ratios.

Flow Cytometry Analysis
HeLa or Caco-2 cells were transfected with pdEYFP-C1amp
containing YFP-fusions of BCL2, Protein A, XIAP, nleF and an
nleF fragment (amino acids 1–160). Apoptosis was induced for 6 h,
48 hours after transfection. Subsequently, the cells were harvested
and stained with propidium iodide (PI) and annexin-V-allophycocyanine (APC) (both BD Biosciences Pharmingen) for detection of
necrotic and apoptotic cells, respectively. PI and Annexin-V-APC
staining was performed following the manufacturer’s instructions.
Flow cytometry was performed using the BD FACSCanto II flow
cytometer with a 488 nm laser. PI, Annexin-APC and YFP were
measured with a 670 nm long pass filter, a 660/20 nm and a 530/
30 nm band pass filter, respectively. Blots were analyzed using the
FACSDiva software (BD Biosciences).

Protein Purification, Crystallisation and Structure
Determination
The catalytic domain of caspase-9 (residues 140–416) and NleF
(1–189) were co-expressed as His6- and GST-tagged fusion
proteins, respectively, and co-purified via affinity chromatography
against the GST-tag. After proteolytic cleavage of the GST-tag by
enterokinase, the complex was purified by a second affinity
chromatography step (Ni-NTA) against the NleF-fused His6 tag.
Finally, a gel filtration chromatography step was performed to
obtain the purified caspase-9-NleF complex. The protein complex
was concentrated to 20 mg/ml in the final protein buffer (25 mM
Hepes pH 7.5, 250 mM NaCl), and subjected to initial screening
for appropriate crystallographic conditions. Initial crystals were
obtained from a reservoir condition containing 0.75 M potassiumsodium tartrate. Data were collected under cryo-conditions at the
Swiss Light Source, Villigen, Switzerland, using 15% (V/V)
ethylene glycol in reservoir solution as cryoprotectant. Data were
processed using XDS [37], phases were obtained by molecular
replacement with Phaser [38] using the monomeric caspase-9
from the publicly available protease dimer [12] as a search model.
Manual model building and refinement was done using Coot [39]
and Refmac5 [40], respectively. Data collection and refinement
statistics are listed in Table S2. Coordinates and reflection data
have been deposited with the Protein Data Bank (www.pdb.org).

Determination of the Kd for Caspase-9/NleF Interaction
Binding kinetic and affinity was analysed on samH5 BLUE and
samH5 GREEN instruments (SAW Instruments GmbH, Bonn,
Germany). Both instruments use the "surface acoustic wave"principle for label-free analysis of molecular binding in a flowthrough system as described in Perpeet et al. (2006) [36].
The Kd of NleF binding to immobilized caspase-9 was
determined using the OriginPro 8.5-based FitMaster. A model
derived from 1:1 binding was applied. BSA and Protein A
references were subtracted for obtained data, respectively.

Detection of Caspase Activity in Cell Lysates
Caspase activity in lysates of HeLa cells was determined using
the caspase-9 fluorometric assay kit APOPCYTO (MBL). Basic
activity that could not be inhibited by the caspase inhibitor
LEHD-FMK was substracted from caspase value. Caspase-9
inhibition in cell lysates by purified NleF was performed using
2.5 mg NleF per 25 ml HeLa cell lysate prepared from 25,000 cells.
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(FLICATM) labeling (VybrantH FAM Caspase-3 and -7 Assay Kit)
performed as per manufacturer’s instructions.

The structural model has been validated via the Molprobity [41]
server yielding an overall score of 1.02 (100th percentile) and a
Clashscore of 0.25 (100th percentile), emphasizing the excellent
quality of the structural model.

Accession Numbers

Generation of NleF Mutations for Binding Assays

The coordinates of the structures reported here have been
submitted to PDB under accession number 3V3K.

Site-directed mutagenesis of the NleF C-terminus was done
using modified reverse primers along with the ECs1815 forward
primer. For the NleF addition/deletion mutants, namely NleF+1
(plus one additional alanine), NleF-1 (Gly189 removed), NleF-4
(the last four amino acids removed), NleF 1–145 and NleF 1–160,
the reverse primers 59-C TGG GTG GAT TCA ACA TTG TAA
AGA TCC TTT GTT G-39, 59-C TGG GTG GAT TCA CGC
TCC ACA TTG TAA AGA TCC TTT GTT G-39 59-C TGG
GTG GAT TCA AGA TCC TTT GTT GTA AGT AAG ATC39, 59-C TGG GTG GAT TCA GAG GCA TTT CAT TGC
TCG TAG-39 and 59-C TGG GTG GAT TCA ATG CGG ACA
TAG CAG ATT ATA AAC-39 were used, respectively. The
construction of NleF 144–189 and NleF 160–189 required the
forward primers 59-A GGC Tcc acc ATG CAT CAC TCT TCA
GAG CTA TAT GG-39 and 59-AGGCTccaccATGTATGGTGATCTACGAGCAATG-39, respectively, along with the
ECs1815 reverse primer. The five C-terminal substitution mutants
of NleF, namely NleF L186A, NleF Q187A, NleF C188A, C188S
and NleF G189A were constructed using the reverse primers 59-C
TGG GTG GAT TCA TCC ACA TTG GGC AGA TCC TTT
GTT G-39, 59-C TGG GTG GAT TCA TCC ACA TGC TAA
AGA TCC TTT GTT G-39, 59-C TGG GTG GAT TCA TCC
AGC TTG TAA AGA TCC TTT GTT G-39, 59-C TGG GTG
GAT TCA TCC AGA TTG TAA AGA TCC TTT GTT G-39
and 59-C TGG GTG GAT TCA TGC ACA TTG TAA AGA
TCC TTT GTT G-39, respectively. After attachment of the attB
sites in a second PCR standardized for GatewayH cloning, the
resulting PCR product was shuttled in the pDONR221 entry
vector, as described in the manufacturer’s instructions (Invitrogen).
NleF +18 (random amino acids) was generated by removal of the
native stop codon. Each construct was sequenced for verification
purposes. The stability of all NleF versions was assessed by
expression as renilla luciferase tagged proteins in HEK-293T cells
(Table S3).

Supporting Information
Figure S1 Interference of NleF with apoptosis signalling. Abbreviations: TRAIL: Tumor necrosis factor Related
Apoptosis Inducing Ligand, FADD: FAS-Associated protein with
Death Domain, BID: BH3 interacting domain Death antagonist,
tBID: trancated BID, TRAIL-R1: TRAIL Receptor 1, ER:
Endoplasmic reticulum. Modified after [46].
(PDF)
Figure S2 Interaction of Caspase-9, 8 and 4 with wild
type and truncated versions of NleF. Numbers indicate
amino acids present in the deleted versions. wt, wild type (amino
acid 1 to 189).
(PDF)
Figure S3 FACS analysis of wild type NleF in HeLa cells
in comparison to Protein A (negative control) and XIAP.
FACS analysis of 10,000 HeLa cells. Apoptosis was induced via
TRAIL for 6 h. PI: propidium iodine, APC: allophycocyanin.
(PDF)
Figure S4

Figure S5 NleF is not a dimer. LUMIER assay of NleF
against itself and against caspase-9.
(PDF)
Figure S6 Relative expression of nleF in cultures
activated for 3 hours in DMEM/F12. Strains complemented
in single copy, DnleF+nleF and DnleF+nleF-4AA, had significantly
higher levels of nleF expression than the wild type E2348/69
strain. Significance was determined using the two-tailed Wilcoxon
test *p#0.05.
(PDF)
Table S1 On/off rates and Kd values of the caspase-9/NleF
interaction. Binding kinetics were measured five times and the
average values are shown.
(DOCX)

Generation and Characterization of Mutant NleF Strains
The nleF gene of EPEC strain E2348/69 [42] was replaced
using phage lambda red recombination [43] with a 75 bp scar
amplified with primers NleF_F6 59-tat cca gat ata tta gtt gta ata
ata ttt atg gat tta ttt gtt aag ggg gtt ttg atG TGA AGG CTG GAG
CTG CTT C-39(upper case letters are complimentary to the
cassette) and NleF_R6 59-gac ggt cac ttt taa gaa aag gca ttt aca cag
aat cct aaa cag gct cac agg cct cta aATC CTC CTT AGT TCC
TAT TCC-39. The resulting DnleF strain was complemented in
single copy at the chromosomal Tn7 attachment site [44] by
placement of nleF variants under the control of the per promoter
[45]. Relative expression of nleF was determined from RNA
extracted from cultures activated for 3 hours in DMEM/F12 using
the TRIzolH Reagent. qRT-PCR was performed using SYBR
green on a model Mx3005P thermocylcer (Stratagene) with
control primers gyr_F 59- GTCTGCGCGACAAGCGCGA-39
and gyr_R 59-GAAACCTGCCAGGTGAGTACC-39 and nleF
primers nleF_F5 59- GGAATGACGATAGAGGATAGGGATAGTTAT-39 and nleF_R5 59- AGGATTAAAATCATCACTGCATCCTTCCACG-39.
The level of activated caspase 3/7 of infected HeLa cells was
assessed using flow cytometry by fluorescent inhibitor of caspases
PLOS ONE | www.plosone.org

Stereo structure of the NleF-Caspase-9 com-

plex.
(PDF)

Table S2 Data collection and refinement statistics for caspase-9
and NleF co-crystallisation.
(DOCX)
Table S3 Expression of the mutagenized NleF. N-terminally
renilla luciferase-tagged NleF was expressed in HEK-293T cells
and luciferase activity was measured in 10 ml HEK-293 cell lysate.
The effects of NleF mutations on NleF protein levels as measured
by luciferase activity are insufficient to explain the differential
effects on caspase activity and apoptotic induction.
(DOCX)
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